Compelling preclinical study results
Preclinical studies have shown that SBP-101 produces superior anti-tumor activity in human cancer cell lines compared to gemcitabine or nab-paclitaxel, alone or in combination, standard of care chemotherapy drugs used to treat pancreatic cancer.
Sun BioPharma’s novel approach
The Company believes that SBP-101 will have a distinct advantage over current pancreatic cancer* therapies in that it specifically targets the exocrine pancreas and can cause ablation, or pharmaceutical resection, of the acinar cells, as well as the primary and metastatic pancreatic cancer, while leaving the insulin-producing islet cells and most non-pancreatic tissue unharmed. Most current cancer therapies (including chemotherapy, radiation or surgery) are associated with significant side effects that further reduce the patient’s quality of life. Read More »
*pancreatic ductal adenocarcinoma
President and Chief Executive Officer
Vice President and Chief Financial Officer
Michael Walker, M.D.
Director of Pancreatic Research
Michael Cullen, MD
Executive Chairman of the Board
Thomas Neenan, Ph.D.
Chief Scientific Officer
VP of Operations
Adelaide Cancer Centre
Cedars-Sinai Medical Center
University of Florida
Mayo Clinic Scottsdale
University of Minnesota
Moffitt Cancer Center
Ohio State James Cancer Center